CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: February-16-18
Credit Expiration Date: February-16-19


Mary Beth Scholand, MD
Associate Professor of Pulmonary Medicine
Director of the Interstitial Lung Disease Clinic
University of Utah
Salt Lake City, UT

Additional Content Development Faculty
Sonye K. Danoff, MD, PhD
Associate Professor of Medicine
Co-Director, Johns Hopkins ILD/IPF Program
Associate Director, Johns Hopkins Myositis Center
Baltimore, MD

Kevin R. Flaherty, MD, MS
Professor of Medicine
Director, University of Michigan Interstitial Lung Disease Program
Chair, Pulmonary Fibrosis Foundation
Clinical Care Network/Registry Steering Committee
Ann Arbor, MI

David J. Lederer, MD, MS
Associate Professor of Medicine
Co-Director, Interstitial Lung Disease Program
Columbia University Medical Center
New York, NY

Credit Hours



Online Presentation

Program Description

Many patients with interstitial lung disease (ILD) do not receive a timely and accurate diagnosis prior to considerable disease progression. Management guidelines are vague and treatment options have been limited, leading to negative health outcomes and decreased quality of life. Advances in diagnostic strategies, recently approved therapies, and new clinical trial data, however, are changing best practices in the diagnosis and treatment of ILD. This activity will examine the signs and symptoms of ILD, strategies for timely diagnosis and accurate classification, and pharmacologic and nonpharmacologic treatment options.

Program Developer/Facilitator


Target Audience

Pulmonologists, internal medicine specialists, primary care clinicians, radiologists, and other clinicians who encounter ILD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Review the diagnosis and classification of ILD disorders.
  2. Discuss advances in ILD diagnosis and assessment.
  3. Outline treatment strategies for ILD.
  4. Recognize the importance of treating comorbidities.


It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our educational programs. Faculty and course directors have disclosed relevant financial relationships with commercial companies, and Penn State has a process in place to resolve any conflict of interest.

Dr. Scholand has disclosed the following:
Speakers bureau: Roche/Genentech
Consultant: Boehringer Ingelheim, Roche/Genentech

Dr. Danoff has disclosed the following:
Grant/research support: Boehringer Ingelheim, Roche/Genentech
Consultant: Boehringer Ingelheim

Dr. Flaherty has disclosed the following:
Grant/research support: Boehringer Ingelheim, Roche/Genentech
Consultant: Aeolus, Afferent, Boehringer Ingelheim, Fibrogen, Roche/Genentech, Sanofi-Genzyme, Veracyte

Dr. Lederer has disclosed the following:
Consultant: FibroGen, Global Blood Therapeutics, Inc., Philips Respironics, Roche/Genentech, Sanofi Genzyme, Veracyte

Penn State staff involved in the development and review of this activity have nothing to disclose.

MCM Education staff involved in the development and review of this activity have nothing to disclose.

Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult full prescribing information before using any product mentioned in this activity. If using products in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosages and uses of the drugs. Neither the publisher nor the providers promote the use of any agent outside of approved labeling.

Credit Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and MCM Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Penn State College of Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit, contact Penn State Continuing Education at 717-531-6483 or Please reference activity code G6190-18-T.

Commercial Support Statements

Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Certificate Fee



The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions; the publisher; Penn State College of Medicine; or Boehringer Ingelheim Pharmaceuticals, Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu